Taking either one of the antihypertensive medications lisinopril or carvedilol when initiating treatment with trastuzumab did not appear to prevent heart function decline in patients with breast cancer, but a subgroup of patients who were also receiving anthracycline-based chemotherapy in addition to trastuzumab benefitted with a significantly reduced risk of heart damage, according to a study.
The latest-generation left ventricular assist device (LVAD) HeartMate 3 is clinically superior to its predecessor HeartMate II in improving survival at 2 years free of disabling stroke or reoperation due to device malfunction in patients with advanced heart failure (HF), the MOMENTUM* 3 trial has shown.
The interleukin-1 beta (IL-1β) inhibitor canakinumab did not prevent the progression from pre-diabetes to diabetes in patients with prior myocardial infarction (MI), according to results of the CANTOS* trial.
The use of aspirin in older patients with type 2 diabetes (T2D) and heart failure appears to reduce mortality risk but paradoxically increases the rates of nonfatal myocardial infarction (MI) and stroke, according to a retrospective analysis of health records presented at ACC.18.
Delayed administration of ticagrelor after fibrinolysis appears to be as safe as clopidogrel with regards to TIMI* major bleeding risk at 30 days in patients younger than 75 years with ST-segment elevation myocardial infarction (STEMI), according to the TREAT** trial. However, there were more minor and minimal bleeding events with ticagrelor than with clopidogrel.
Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.
Not only does treatment with the PCSK9* inhibitor alirocumab reduces cardiovascular (CV) events along with plunges in LDL-C levels, it was also associated with a reduced risk of all-cause mortality compared with placebo in patient with a recent acute coronary syndrome (ACS) and persistently high cholesterol despite maximal statin therapy, according to top-line results from the ODYSSEY** Outcomes trial.
The experimental reversal agent andexanet alfa effectively reversed the anticoagulant effect of factor Xa (fXa) inhibitors by controlling serious bleeding events, according to interim results of the ANNEXA-4* trial presented at the American College of Cardiology Annual Scientific Session & Expo (ACC.18) in Orlando, Florida, US.
Patients with acute coronary syndrome (ACS) who received a 6-month course of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) fared similarly to those who received the standard ≥12-month DAPT course with regards to incidence of major adverse cardiovascular and cerebrovascular events 18 months post-procedure, according to results from the SMART-DATE* trial. However, a higher incidence of myocardial infarction (MI) with 6-month DAPT precludes it from replacing the standard course.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.